Trending Clinical Topics for January 2018

Ryan Syrek

Disclosures

January 26, 2018

Each week, we identify one top search term, speculate as to what caused its popularity, and provide an infographic on a related condition. If you have thoughts about what's trending and why, feel free to share them with us on Twitter or Facebook!

Clinical Trend of the Week (January 20-26): Olaparib

A specific indication for a cancer drug resulted in this week’s top search term. For the first time, the US Food and Drug Administration (FDA) has approved a drug specifically indicated for use in BRCA-mutated metastatic breast cancer. A phase 3 randomized trial showed that certain breast cancers are sensitive to therapy targeted at defects in DNA damage-repair pathways. Olaparib inhibits the enzyme poly-(ADP-ribose) polymerase (PARP), which potentially leads to a decrease in or cessation of tumor growth. First approved in 2014, olaparib was initially for use in patients who received three or more prior lines of chemotherapy. New epidemiologic estimates suggest that in 2018, breast cancer will account for approximately 30% of new cancer diagnoses in women. Given that figure, it’s no wonder that this new indication propelled olaparib to the top of this week’s searches.  

For more information on breast cancer, read here.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....